A large body of work have extensively studied and evaluated potential clinical applications of agonists and antagonists of GHRH in diverse fields, including oncology, endocrinology, obesity, diabetes, other metabolic dysfunctions, cardiology, immune functions, mood disorders, Alzheimer’s and lung disease, ophthalmology, inflammation, wound healing and other applications. This evidence concerns the gene GHRH and obesity due to melanocortin 4 receptor deficiency.